A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.

A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation. - A cerebrospinal fluid transitivity identification test of afatinib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014065

Enrollment

Registered

2014-05-26

Start date

2014-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carcinomatous meningitis patients with NSCLC harboring EGFR mutation

Interventions

Afatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. NSCLC, EGFR mutation positive, carcinomatous meningitis patients 2. no treatment of afatinib 3. over 20 years old at the registration 4. ECOG PS 0-3 5. good status of main organ 6. written informed concent

Exclusion criteria

Exclusion criteria: 1. over Grade 2 of diarrhea, a severe gastrointestinal disorder 2. Interstitial lung disease 3. diagnose of malignancy in 5 years 4. Angina and myocardial infarction within six months, heart disorder, severe arrhythmia 5. pleural effusion or ascites which need treatment 6. uncontrolled complications 7. Serious drug allergy history 8. Cannot promise contraception 9. No pregnancy, during nursing 10. A chief physician decide not eligible

Design outcomes

Primary

Measure	Time frame
Cerebrospinal fluid transitivity of afatinib	—

Secondary

Measure	Time frame
efficacy and safety of afatinib	—

Countries

Japan

Contacts

Public ContactAkihiro Tamiya

Kinki-Chuo Chest Medical Center Internal Medicine

atamiya@kch.hiosp.go.jp072-252-3021

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026